Protozoan parasites and type I interferons: A cold case reopened

Trends in Parasitology

Volumn 30, Issue 10, 2014, Pages 491-498

  Beiting, Daniel P ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Immunity; Infection; Intracellular parasite; Protozoan; Type I interferon

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GAMMA INTERFERON; INTERFERON; TYPE I INTERFERON;

HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IN VIVO STUDY; LEISHMANIA; NONHUMAN; OUTCOME ASSESSMENT; PARASITOSIS; PLASMODIUM FALCIPARUM; PROTOZOON; REVIEW; SIGNAL TRANSDUCTION; TOXOPLASMA GONDII; TRYPANOSOMA; TRYPANOSOMA BRUCEI; TRYPANOSOMA CRUZI; ANIMAL; EUKARYOTE; GENE EXPRESSION REGULATION; GENETICS; HOST PARASITE INTERACTION; IMMUNITY; IMMUNOLOGY; INFECTION; INTRACELLULAR PARASITE; METABOLISM; PROTOZOAL INFECTION;

IMMUNITY; INFECTION; INTRACELLULAR PARASITE; PROTOZOAN; TYPE I INTERFERON;

ANIMALS; EUKARYOTA; GENE EXPRESSION REGULATION; HOST-PARASITE INTERACTIONS; HUMANS; INTERFERON TYPE I; INTERFERON-GAMMA; PROTOZOAN INFECTIONS;

EID: 84908031613     PISSN: 14714922     EISSN: 14715007     Source Type: Journal    
DOI: 10.1016/j.pt.2014.07.007     Document Type: Review

References (97)

1. Isaacs A., Lindenmann J. Virus interference. I. The interferon. Proc. R. Soc. Lond. B: Biol. Sci. 1957, 147:258-267.
2. Crotta S., et al. Type I and type III interferons drive redundant amplification loops to induce a transcriptional signature in influenza-infected airway epithelia. PLoS Pathog. 2013, 9:e1003773.
3. Sommereyns C., et al. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog. 2008, 4:e1000017.
4. Ank N., et al. An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J. Immunol. 2008, 180:2474-2485.
5. Fu X.Y., et al. ISGF3, the transcriptional activator induced by interferon alpha, consists of multiple interacting polypeptide chains. Proc. Natl. Acad. Sci. U.S.A. 1990, 87:8555-8559.
6. Levy D.E., et al. Interferon-induced nuclear factors that bind a shared promoter element correlate with positive and negative transcriptional control. Genes Dev. 1988, 2:383-393.
7. Decker T., et al. GAS elements: a few nucleotides with a major impact on cytokine-induced gene expression. J. Interferon Cytokine Res. 1997, 17:121-134.
8. Suzuki Y., et al. Interferon-gamma: the major mediator of resistance against Toxoplasma gondii. Science 1988, 240:516-518.
9. Yap G.S., Sher A. Effector cells of both nonhemopoietic and hemopoietic origin are required for interferon (IFN)-gamma- and tumor necrosis factor (TNF)-alpha-dependent host resistance to the intracellular pathogen, Toxoplasma gondii. J. Exp. Med. 1999, 189:1083-1092.
10. Hayward A.R., et al. Interferon-gamma is required for innate immunity to Cryptosporidium parvum in mice. J. Infect. Dis. 2000, 182:1001-1004.
11. + effector cells default to the Th2 pathway in interferon gamma-deficient mice infected with Leishmania major. J. Exp. Med. 1994, 179:1367-1371.
12. Silva J.S., et al. Interleukin 10 and interferon gamma regulation of experimental Trypanosoma cruzi infection. J. Exp. Med. 1992, 175:169-174.
13. Chaussabel D., et al. Unique gene expression profiles of human macrophages and dendritic cells to phylogenetically distinct parasites. Blood 2003, 102:672-681.
14. Prudencio M., et al. The silent path to thousands of merozoites: the Plasmodium liver stage. Nat. Rev. Microbiol. 2006, 4:849-856.
15. Newton C.R., et al. Cerebral malaria. J. Neurol. Neurosurg. Psychiatry 2000, 69:433-441.
16. Liehl P., et al. Host-cell sensors for Plasmodium activate innate immunity against liver-stage infection. Nat. Med. 2014, 20:47-53.
17. Portugal S., et al. Host-mediated regulation of superinfection in malaria. Nat. Med. 2011, 17:732-737.
18. Miller J.L., et al. Interferon-mediated innate immune responses against malaria parasite liver stages. Cell Rep. 2014, 7:436-447.
19. Pichlmair A., et al. IFIT1 is an antiviral protein that recognizes 5'-triphosphate RNA. Nat. Immunol. 2011, 12:624-630.
20. Kane M., et al. MX2 is an interferon-induced inhibitor of HIV-1 infection. Nature 2013, 502:563-566.
21. Ferreira A., et al. Inhibition of development of exoerythrocytic forms of malaria parasites by gamma-interferon. Science 1986, 232:881-884.
22. Schofield L., et al. Interferon-gamma inhibits the intrahepatocytic development of malaria parasites in vitro. J. Immunol. 1987, 139:2020-2025.
23. The RTS,S Clinical Trials Partnership A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N. Engl. J. Med. 2012, 367:2284-2295.
24. + T cell immunity. Science 2011, 334:475-480.
25. Manns M.P., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
26. Imwong M., et al. Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. J. Infect. Dis. 2007, 195:927-933.
27. Chen N., et al. Relapses of Plasmodium vivax infection result from clonal hypnozoites activated at predetermined intervals. J. Infect. Dis. 2007, 195:934-941.
28. Gething P.W., et al. A long neglected world malaria map: Plasmodium vivax endemicity in 2010. PLoS Negl. Trop. Dis. 2012, 6:e1814.
29. Sharma S., et al. Innate immune recognition of an AT-rich stem-loop DNA motif in the Plasmodium falciparum genome. Immunity 2011, 35:194-207.
30. Kim C.C., et al. Splenic red pulp macrophages produce type I interferons as early sentinels of malaria infection but are dispensable for control. PLoS ONE 2012, 7:e48126.
31. + dendritic cells, not plasmacytoid dendritic cells, induce T cell responses to Plasmodium chabaudi malaria. Int. J. Parasitol. 2010, 40:711-719.
32. Kim C.C., et al. Experimental malaria infection triggers early expansion of natural killer cells. Infect. Immun. 2008, 76:5873-5882.
33. + T-cell-dependent parasite control during blood-stage Plasmodium infection. Eur. J. Immunol. 2011, 41:2688-2698.
34. Melo M.B., et al. Transcriptional analysis of murine macrophages infected with different Toxoplasma strains identifies novel regulation of host signaling pathways. PLoS Pathog. 2013, 9:e1003779.
35. Beiting D.P., et al. Differential induction of TLR3-dependent innate immune signaling by closely related parasite species. PLoS ONE 2014, 9:e88398.
36. Lieberman L.A., et al. STAT1 plays a critical role in the regulation of antimicrobial effector mechanisms, but not in the development of Th1-type responses during toxoplasmosis. J. Immunol. 2004, 172:457-463.
37. Orellana M.A., et al. Role of beta interferon in resistance to Toxoplasma gondii infection. Infect. Immun. 1991, 59:3287-3290.
38. Nagineni C.N., et al. Mechanisms of interferon-induced inhibition of Toxoplasma gondii replication in human retinal pigment epithelial cells. Infect. Immun. 1996, 64:4188-4196.
39. Demar M., et al. Acute toxoplasmoses in immunocompetent patients hospitalized in an intensive care unit in French Guiana. Clin. Microbiol. Infect. 2012, 18:E221-E231.
40. Ajzenberg D. Unresolved questions about the most successful known parasite. Expert Rev. Anti Infect. Ther. 2011, 9:169-171.
41. Grigg M.E., et al. Unusual abundance of atypical strains associated with human ocular toxoplasmosis. J. Infect. Dis. 2001, 184:633-639.
42. Anderson M.L., et al. Evidence of vertical transmission of Neospora sp infection in dairy cattle. J. Am. Vet. Med. Assoc. 1997, 210:1169-1172.
43. Abou-Bacar A., et al. Role of gamma interferon and T cells in congenital Toxoplasma transmission. Parasite Immunol. 2004, 26:315-318.
44. Rosowski E.E., et al. Toxoplasma gondii inhibits gamma interferon (IFN-gamma)- and IFN-beta-induced host cell STAT1 transcriptional activity by increasing the association of STAT1 with DNA. Infect. Immun. 2014, 82:706-719.
45. Kim S.K., et al. Toxoplasma gondii dysregulates IFN-gamma-inducible gene expression in human fibroblasts: insights from a genome-wide transcriptional profiling. J. Immunol. 2007, 178:5154-5165.
46. Luder C.G., et al. Toxoplasma gondii down-regulates MHC class II gene expression and antigen presentation by murine macrophages via interference with nuclear translocation of STAT1alpha. Eur. J. Immunol. 2001, 31:1475-1484.
47. Rosowski E.E., Saeij J.P. Toxoplasma gondii clonal strains all inhibit STAT1 transcriptional activity but polymorphic effectors differentially modulate IFNgamma induced gene expression and STAT1 phosphorylation. PLoS ONE 2012, 7:e51448.
48. Zimmermann S., et al. Induction of suppressor of cytokine signaling-1 by Toxoplasma gondii contributes to immune evasion in macrophages by blocking IFN-gamma signaling. J. Immunol. 2006, 176:1840-1847.
49. Lang C., et al. Impaired chromatin remodelling at STAT1-regulated promoters leads to global unresponsiveness of Toxoplasma gondii-infected macrophages to IFN-gamma. PLoS Pathog. 2012, 8:e1002483.
50. Mattner J., et al. Regulation of type 2 nitric oxide synthase by type 1 interferons in macrophages infected with Leishmania major. Eur. J. Immunol. 2000, 30:2257-2267.
51. Diefenbach A., et al. Type 1 interferon (IFNalpha/beta) and type 2 nitric oxide synthase regulate the innate immune response to a protozoan parasite. Immunity 1998, 8:77-87.
52. Mattner J., et al. Protection against progressive leishmaniasis by IFN-beta. J. Immunol. 2004, 172:7574-7582.
53. Colina R., et al. Translational control of the innate immune response through IRF-7. Nature 2008, 452:323-328.
54. Jaramillo M., et al. Leishmania repression of host translation through mTOR cleavage is required for parasite survival and infection. Cell Host Microbe 2011, 9:331-341.
55. Novais F.O., et al. Genomic profiling of human Leishmania braziliensis lesions identifies transcriptional modules associated with cutaneous immunopathology. J. Invest. Dermatol. 2014, 10.1038/jid.2014.305.
56. Novais F.O., et al. Human classical monocytes control the intracellular stage of Leishmania braziliensis by reactive oxygen species. J. Infect. Dis. 2014, 209:1288-1296.
57. Khouri R., et al. IFN-beta impairs superoxide-dependent parasite killing in human macrophages: evidence for a deleterious role of SOD1 in cutaneous leishmaniasis. J. Immunol. 2009, 182:2525-2531.
58. Chessler A.D., et al. Trypanosoma cruzi triggers an early type I IFN response in vivo at the site of intradermal infection. J. Immunol. 2009, 182:2288-2296.
59. Vaena de Avalos S., et al. Immediate/early response to Trypanosoma cruzi infection involves minimal modulation of host cell transcription. J. Biol. Chem. 2002, 277:639-644.
60. Chessler A.D., et al. A novel IFN regulatory factor 3-dependent pathway activated by trypanosomes triggers IFN-beta in macrophages and fibroblasts. J. Immunol. 2008, 181:7917-7924.
61. Chessler A.D., et al. Type I interferons increase host susceptibility to Trypanosoma cruzi infection. Infect. Immun. 2011, 79:2112-2119.
62. Amin D.N., et al. Distinct Toll-like receptor signals regulate cerebral parasite load and interferon alpha/beta and tumor necrosis factor alpha-dependent T-cell infiltration in the brains of Trypanosoma brucei-infected mice. J. Infect. Dis. 2012, 205:320-332.
63. Lopez R., et al. Type I IFNs play a role in early resistance, but subsequent susceptibility, to the African trypanosomes. J. Immunol. 2008, 181:4908-4917.
64. Une C., et al. Role of IFN-alpha/beta and IL-12 in the activation of natural killer cells and interferon-gamma production during experimental infection with Trypanosoma cruzi. Clin. Exp. Immunol. 2003, 134:195-201.
65. + T-cell immunity is unaffected by the absence of type I interferon signaling. Infect. Immun. 2010, 78:3154-3159.
66. Manry J., et al. Evolutionary genetic dissection of human interferons. J. Exp. Med. 2011, 208:2747-2759.
67. Manry J., et al. Evolutionary genetics evidence of an essential, nonredundant role of the IFN-gamma pathway in protective immunity. Hum. Mutat. 2011, 32:633-642.
68. Gough D.J., et al. Constitutive type I interferon modulates homeostatic balance through tonic signaling. Immunity 2012, 36:166-174.
69. Gough D.J., et al. Functional crosstalk between type I and II interferon through the regulated expression of STAT1. PLoS Biol. 2010, 8:e1000361.
70. Mack E.A., et al. Type 1 interferon induction of natural killer cell gamma interferon production for defense during lymphocytic choriomeningitis virus infection. MBio 2011, 2:e00169-e211.
71. Gautier G., et al. A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. J. Exp. Med. 2005, 201:1435-1446.
72. Vigario A.M., et al. Recombinant human IFN-alpha inhibits cerebral malaria and reduces parasite burden in mice. J. Immunol. 2007, 178:6416-6425.
73. Rayamajhi M., et al. Induction of IFN-alphabeta enables Listeria monocytogenes to suppress macrophage activation by IFN-gamma. J. Exp. Med. 2010, 207:327-337.
74. O'Connell R.M., et al. Type I interferon production enhances susceptibility to Listeria monocytogenes infection. J. Exp. Med. 2004, 200:437-445.
75. - DCs impairs Th1-dependent malaria immunity. J. Clin. Invest. 2014, 124:2483-2496.
76. Teles R.M., et al. Type I interferon suppresses type II interferon-triggered human anti-mycobacterial responses. Science 2013, 339:1448-1453.
77. Teijaro J.R., et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 2013, 340:207-211.
78. Wilson E.B., et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 2013, 340:202-207.
79. Wang Y., et al. Timing and magnitude of type I interferon responses by distinct sensors impact CD8 T cell exhaustion and chronic viral infection. Cell Host Microbe 2012, 11:631-642.
80. + T cell memory. Immunity 2014, 40:801-813.
81. Kernbauer E., et al. Route of infection determines the impact of type I interferons on innate immunity to Listeria monocytogenes. PLoS ONE 2013, 8:e65007.
82. Iwasaki A. A virological view of innate immune recognition. Annu. Rev. Microbiol. 2012, 66:177-196.
83. Koblansky A.A., et al. Recognition of profilin by Toll-like receptor 12 is critical for host resistance to Toxoplasma gondii. Immunity 2013, 38:119-130.
84. Alexopoulou L., et al. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001, 413:732-738.
85. Wang A.L., Wang C.C. Viruses of the protozoa. Annu. Rev. Microbiol. 1991, 45:251-263.
86. Weeks R., et al. LRV1 viral particles in Leishmania guyanensis contain double-stranded or single-stranded RNA. J. Virol. 1992, 66:1389-1393.
87. Patterson J.L. Viruses of protozoan parasites. Exp. Parasitol. 1990, 70:111-113.
88. Ives A., et al. Leishmania RNA virus controls the severity of mucocutaneous leishmaniasis. Science 2011, 331:775-778.
89. Zangger H., et al. Leishmania aethiopica field isolates bearing an endosymbiontic dsRNA virus induce pro-inflammatory cytokine response. PLoS Negl. Trop. Dis. 2014, 8:e2836.
90. Aksoy E., et al. Double-stranded RNAs from the helminth parasite Schistosoma activate TLR3 in dendritic cells. J. Biol. Chem. 2005, 280:277-283.
91. Bernard J.J., et al. Ultraviolet radiation damages self noncoding RNA and is detected by TLR3. Nat. Med. 2012, 18:1286-1290.
92. Wu X., et al. Protein-DNA complex is the exclusive malaria parasite component that activates dendritic cells and triggers innate immune responses. J. Immunol. 2010, 184:4338-4348.
93. Parroche P., et al. Malaria hemozoin is immunologically inert but radically enhances innate responses by presenting malaria DNA to Toll-like receptor 9. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:1919-1924.
94. Kalantari P., et al. Dual engagement of the NLRP3 and AIM2 inflammasomes by Plasmodium-derived hemozoin and DNA during malaria. Cell Rep. 2014, 6:196-210.
95. Bogdan C., et al. The role of type I interferons in non-viral infections. Immunol. Rev. 2004, 202:33-48.
96. Beiting D.P., Roos D.S. A systems biological view of intracellular pathogens. Immunol. Rev. 2011, 240:117-128.
97. Aurrecoechea C., et al. EuPathDB: the eukaryotic pathogen database. Nucleic Acids Res. 2013, 41:D684-D691.